Boundless Bio Stock Up 87% on Failed Drug and Reverse Merger Deal

Boundless Bio’s cancer drug did not work. The company is cutting three-quarters of its staff. Its stock went up 87%.

Boundless Bio Hands Control to a Private Gene-Editing Startup After Its Lead Drug Fails

On June 22, Boundless Bio (Nasdaq: BOLD) signed a definitive merger agreement with Serapha Bio, a privately held company developing a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD — a hereditary disorder in which the liver produces a misfolded protein instead of the alpha-1 antitrypsin that normally protects the lungs, eventually causing liver and lung damage in up to 100,000 Americans). The announcement, made June 23, came packaged with the reason it was happening: Boundless’s own lead cancer candidate had failed.

BBI-940’s human pharmacokinetic exposure (how much of the drug actually reaches the bloodstream at a given dose) came in significantly lower than preclinical animal studies had predicted. Early data from the KOMODO-1 trial did not support continuing development. Boundless is cutting roughly 75% of its workforce, with CEO Zachary Hornby and key R&D leaders departing July 1. Chief Legal Officer Jessica Oien becomes president during the transition.

Here is the mechanism worth understanding clearly. Serapha is essentially buying Boundless’s Nasdaq listing. Under the merger terms, pre-merger Boundless shareholders end up owning just 3.7% of the combined company. Serapha’s investors, including the new money coming in, own the other 96.3%. Boundless plans to pay its existing shareholders a one-time cash dividend of roughly $44 to $48 million before the deal closes, distributing the company’s remaining cash rather than letting it get diluted into the new venture.

Serapha brings real funding and a real asset. The company secured approximately $230 million in financing, $138 million already closed as a Series A and another $92 million expected at the merger’s close, co-led by RA Capital Management and RTW Investments with participation from Janus Henderson and several other institutional names. Serapha’s lead candidate, SERP-01, is an in vivo base editing therapy licensed from YolTech Therapeutics in China, with proof-of-concept data showing it can restore AAT protein to normal levels. The combined company plans to trade under the ticker AATD, with funding expected to last into the second half of 2029, covering both completion of Phase 2 and the start of Phase 3.

Investors who bought BOLD shares on the 87% pop are not betting on anything Boundless built. They are betting on SERP-01, a gene-editing program developed for a different disease entirely, run by a different management team, that happened to need a public listing. The merger is expected to close in Q4 2026, pending shareholder votes, Nasdaq approval, and antitrust clearance. Filings on SEC EDGAR.

CalciMedica Gets the FDA’s Sign-Off to Keep Going After a Trial Pause Over a Mortality Signal

On June 24, CalciMedica (Nasdaq: CALC) announced that the FDA had reviewed a protocol amendment and interim safety data for its Phase 2 KOURAGE trial and raised no comments or questions, meaning the company can continue dosing patients with Auxora, its lead CRAC channel inhibitor candidate.

The backstory matters here. KOURAGE tests Auxora in patients with severe acute kidney injury (AKI) and associated acute hypoxemic respiratory failure, a population with high mortality and no approved therapies. In January 2026, CalciMedica paused enrollment after its Independent Data Monitoring Committee flagged a mortality imbalance between treatment arms. That kind of signal is the thing every clinical trial fears most. CalciMedica’s internal review, conducted with external experts, found no evidence the drug itself was responsible. Instead, the imbalance traced back to differences in how sick patients were at baseline between the two arms, a study design issue rather than a safety issue with the drug.

CalciMedica submitted a protocol amendment in March addressing patient inclusion criteria and stratification. The FDA’s silent review of that amendment, expiring without objection, clears the path to keep dosing patients. The company is also using Auxora’s now-larger safety database to move into a pulmonary hypertension program, citing preclinical and genetic expression data supporting CRAC channel inhibition in that disease as well. CalciMedica previously reported positive Phase 2b data for Auxora in acute pancreatitis and Phase 2 data in severe COVID-19 pneumonia. Filings on SEC EDGAR.

Upcoming Catalysts: Serapha Merger Vote, KOURAGE Re-Enrollment, AATD Ticker Launch

Boundless/Serapha shareholder vote: the merger needs approval from shareholders of both companies plus Nasdaq listing clearance. Watch for the proxy filing and vote date as the clearest sign the Q4 2026 close timeline is holding.

CalciMedica KOURAGE re-enrollment: the FDA review clears the path, but the trial still needs patients. Watch for confirmation that enrollment has formally resumed under the amended protocol.

CalciMedica pulmonary hypertension program: the company has signaled intent to move directly into this indication using Auxora’s existing safety data. A formal trial initiation announcement is the next concrete step.

Sources

Editorial Disclosure

This roundup is based entirely on publicly available information including press releases, SEC filings, and contemporaneous trade press coverage. Securities discussed include Boundless Bio, Inc. (Nasdaq: BOLD) and CalciMedica, Inc. (Nasdaq: CALC). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. The Boundless Bio and Serapha Bio merger agreement was entered into June 22, 2026 and publicly announced June 23, 2026, confirmed via SEC Form 8-K and Boundless Bio’s investor relations page. The transaction is not yet closed; it remains subject to approval by shareholders of both companies, Nasdaq listing approval for the combined entity, effectiveness of a registration statement with the SEC, Hart-Scott-Rodino antitrust clearance, and other customary closing conditions, and is targeted to close in Q4 2026. Boundless Bio’s lead oncology candidate, BBI-940, is being discontinued following unfavorable Phase 1 pharmacokinetic data; this is disclosed prominently in the article body. Pre-merger Boundless Bio shareholders are expected to retain approximately 3.7% ownership of the combined company following closing, with Serapha Bio investors and pre-closing financing participants expected to hold approximately 96.3%; readers should understand that BOLD’s share price reaction reflects market enthusiasm for Serapha’s pipeline asset rather than any value created by Boundless Bio’s own historical drug development efforts. Serapha Bio’s lead candidate SERP-01 is an investigational in vivo base editing therapy that has not been approved by the FDA; proof-of-concept data referenced in this article is early-stage and has not been validated in a registrational trial. CalciMedica’s press release date is confirmed as June 24, 2026 via SEC Form 8-K. CalciMedica’s KOURAGE trial was paused in January 2026 following an Independent Data Monitoring Committee safety signal involving a mortality imbalance between treatment arms; this history is disclosed in the article body. CalciMedica’s internal and external safety reviews did not identify evidence of drug-related toxicity, but readers should understand that the FDA’s lack of comments on a protocol amendment is not equivalent to an efficacy or safety approval of Auxora; Auxora remains an investigational drug that has not been approved by the FDA for any indication. CalciMedica’s stated intention to pursue a pulmonary hypertension program is a forward-looking plan and no trial has yet been initiated in that indication at the time of publication. These are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.

Boundless Bio Stock Up 87% on Failed Drug and Reverse Merger Deal

Join our Mailing List